E-Scopics Hepatoscope Redefines Liver Care with New FDA Clearance

AIX-EN-PROVENCE, France & ST. LOUIS – May 01, 2026 – Medtech innovator E-Scopics has secured a pivotal U.S. Food and Drug Administration (FDA) clearance for major enhancements to its Hepatoscope® platform, an ultraportable ultrasound system designed for point-of-care liver assessment. The clearance introduces a dedicated spleen examination workflow, brings its elastography imaging to an international standard of excellence, and significantly expands its IT integration capabilities, marking a new era in the non-invasive management of chronic liver disease.

The French-American company announced that these advanced features will be presented to the medical community at the upcoming Digestive Disease Week® (DDW) 2026, a premier global conference for gastroenterology and hepatology professionals. The demonstration will take place from June 3 to 5 at booth #2039 in Chicago, IL. This development signals a significant step forward in making comprehensive liver and spleen assessment more accessible, reliable, and integrated into daily clinical practice.

A New Frontier in Cirrhosis Management

One of the most clinically significant updates is the addition of a dedicated Spleen Exam workflow. This new feature expands Hepatoscope's utility beyond the liver to the non-invasive assessment of cirrhosis complications, particularly portal hypertension—a dangerous increase in pressure within the portal venous system. Traditionally, monitoring this condition often requires invasive procedures like endoscopy to check for esophageal varices, which carry risks and discomfort for the patient.

Spleen stiffness, as measured by elastography, is increasingly recognized by clinicians as a strong surrogate marker for portal hypertension. By enabling this measurement at the bedside, Hepatoscope offers a non-invasive alternative that can help stratify patient risk and potentially reduce the frequency of invasive surveillance. The system's new workflow is specifically optimized for the spleen's unique anatomy, incorporating an adjusted vibration frequency and a tailored region of interest to improve the reliability of stiffness measurements, especially in more severe cases.

Dr. Olivia Pietri, a hepato-gastroenterologist at Saint-Joseph Hospital in Marseille, France, highlighted the practical impact of the device. “Hepatoscope is unique because it combines real-time ultrasound imaging and transient elastography in a single, highly portable device. This allows me to use the system literally at the bedside for hospitalized patients, in the outpatient consultation room, or in my community-based private practice,” she stated. “What is particularly compelling is the ability to assess spleen stiffness under direct image guidance at the bedside. This opens new possibilities for evaluating cirrhotic patients and managing them more proactively, while maintaining the reproducibility and ease of use clinicians need in everyday practice.”

Setting a New Standard in Diagnostic Imaging

Beyond expanding its clinical applications, E-Scopics has also elevated the technical quality of its platform. With this latest clearance, Hepatoscope's 2D Transient Elastography (2DTE) imaging achieves full compliance with the international IEC 63412-1 standard for tissue stiffness mapping. This makes it the first ultraportable liver assessment solution capable of real-time tissue elastography imaging to meet this demanding regulatory benchmark.

The IEC 63412-1 standard is critical because it establishes rigorous technical specifications for the accuracy, reproducibility, and comparability of elastography measurements. For clinicians, this compliance means they can have greater confidence that the stiffness values they measure are reliable and consistent, not only from one exam to the next but also across different devices and locations that adhere to the same standard. This standardization is crucial for monitoring disease progression and a patient's response to treatment, as the system now enables better visualization of even small changes in tissue stiffness.

“Elastography plays an essential role in evaluating the severity of chronic liver diseases by measuring how shear waves propagate through tissue such as the liver and spleen,” said Claude Cohen-Bacrie, founder and CEO of E-Scopics. “The compliance with the IEC 63412-1 standard imposes clear explanations about shear wave propagation speed measurements and optimal visualization of 2DTE. Hepatoscope is now the only ultraportable ultrasound system with both real-time ultrasound imaging plus tissue elasticity imaging, for liver and spleen assessment, at the point of care.” This achievement solidifies the device's position as a leader in diagnostic quality and reliability within the rapidly growing point-of-care market.

Streamlining the Digital Clinic

Recognizing that advanced diagnostic tools are only as effective as their ability to integrate into hospital workflows, E-Scopics has also rolled out significant IT and software enhancements. The Hepatoscope platform, initially launched on Windows, is now compatible with macOS systems running on Apple M3 chips or later. This cross-platform flexibility gives healthcare organizations greater choice in their hardware deployment and simplifies implementation for IT departments managing diverse technological environments.

More profoundly, the platform now conforms with the HL7® FHIR® R4 standard, the leading framework for healthcare data interoperability. This enables direct, secure connectivity with institutional Electronic Health Record (EHR) systems. In practice, this means a clinician can log in, pull up an appointment worklist, select a patient, perform the exam, and have the complete report automatically and securely exported back to the patient's EHR file. This seamless integration drastically reduces administrative burden, minimizes the risk of manual data entry errors, and accelerates exam throughput, allowing clinical teams to focus more on patient care and less on paperwork.

The 'Ultrasound-as-a-Service' Disruption

Underpinning these technological advancements is E-Scopics’ innovative business model: 'Ultrasound-as-a-Service' (UaaS). Instead of requiring a large upfront capital investment, which can be a significant barrier for many clinics and hospitals, the company offers its platform via pay-per-use or subscription models. This approach dematerializes the technology, transforming a costly hardware purchase into a predictable operating expense.

This UaaS model makes state-of-the-art diagnostic tools like Hepatoscope accessible to a much broader range of healthcare settings, from large academic hospitals to smaller community practices and outpatient centers. Subscribers benefit from continuous software updates, maintenance, and support, ensuring they always have the latest capabilities without the traditional lifecycle management and upgrade costs. While this model creates a dependency on the vendor, its financial flexibility and evergreen technology access are powerful disruptors in a market long dominated by traditional equipment sales. By combining cutting-edge, standard-compliant technology with a modern, accessible business model, E-Scopics is poised to significantly impact how chronic liver disease is diagnosed and managed across the healthcare landscape.

This combination of clinical expansion, technical standardization, and workflow integration positions the enhanced Hepatoscope platform as a comprehensive solution for modern hepatology.